Formación Continuada
Terapia con péptidos radiomarcados con [177Lu]Lu-DOTA-TATE
Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE
S. Prado-Wohlwend
, J.C. Bernal-Vergara, A. Utrera-Costero, J.R. Cañón-Sánchez, M. Agudelo-Cifuentes, P. Bello-Arques, en nombre del Grupo de Trabajo de Endocrinología de la SEMNIM
Autor para correspondencia
Servicio de Medicina Nuclear, Hospital Universitario y Politécnico La Fe, Valencia, España
Leído
3394
Vecesse ha leído el artículo
697
Total PDF
2697
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 74 | 3 | 77 |
| 2025 11 | 8 | 12 | 20 |
| 2025 10 | 20 | 4 | 24 |
| 2025 9 | 16 | 4 | 20 |
| 2025 8 | 1 | 2 | 3 |
| 2025 7 | 12 | 3 | 15 |
| 2025 6 | 32 | 2 | 34 |
| 2025 5 | 3 | 4 | 7 |
| 2025 4 | 11 | 9 | 20 |
| 2025 3 | 24 | 3 | 27 |
| 2025 2 | 5 | 10 | 15 |
| 2025 1 | 19 | 5 | 24 |
| 2024 12 | 6 | 0 | 6 |
| 2024 11 | 6 | 9 | 15 |
| 2024 10 | 16 | 11 | 27 |
| 2024 9 | 10 | 4 | 14 |
| 2024 8 | 20 | 5 | 25 |
| 2024 7 | 22 | 9 | 31 |
| 2024 6 | 16 | 4 | 20 |
| 2024 5 | 73 | 23 | 96 |
| 2024 4 | 12 | 12 | 24 |
| 2024 3 | 4 | 5 | 9 |
| 2024 2 | 5 | 4 | 9 |
| 2024 1 | 17 | 7 | 24 |
| 2023 12 | 12 | 7 | 19 |
| 2023 11 | 20 | 23 | 43 |
| 2023 10 | 25 | 8 | 33 |
| 2023 9 | 8 | 4 | 12 |
| 2023 8 | 7 | 5 | 12 |
| 2023 7 | 34 | 11 | 45 |
| 2023 6 | 9 | 6 | 15 |
| 2023 5 | 35 | 10 | 45 |
| 2023 4 | 14 | 7 | 21 |
| 2023 3 | 37 | 7 | 44 |
| 2023 2 | 24 | 12 | 36 |
| 2022 1 | 42 | 13 | 55 |
| 2022 12 | 6 | 9 | 15 |
| 2022 11 | 285 | 24 | 309 |
| 2022 10 | 36 | 26 | 62 |
| 2022 9 | 161 | 12 | 173 |
| 2022 8 | 34 | 9 | 43 |
| 2022 7 | 35 | 11 | 46 |
| 2022 6 | 23 | 22 | 45 |
| 2022 5 | 492 | 32 | 524 |
| 2022 4 | 67 | 25 | 92 |
| 2022 3 | 197 | 51 | 248 |
| 2022 2 | 396 | 63 | 459 |
| 2021 1 | 266 | 131 | 397 |
| 2021 12 | 0 | 15 | 15 |
Mostrar todo
